After signing up, you'll start to receive regular news updates from us.
Celera and Medarex Establish Therapeutic Antibody Collaboration in Cancer
Complete the form below to unlock access to ALL audio articles.
Celera Genomics, an Applera Corporation business, and Medarex, Inc. have announced the formation of a strategic collaboration to discover and develop fully human antibodies for the potential treatment of multiple cancer indications.
The collaboration will encompass the development of therapeutic antibodies against proteins identified by Celera's proteomic research discovery efforts as being over-expressed on the surface of tumor cells and subsequently validated through additional research at Celera.
The collaboration combines Celera's ability to discover and validate targets for oncology with Medarex's expertise in the development of fully human antibody therapeutics.
Under the collaboration, Celera and Medarex plan to jointly select targets from Celera's portfolio of cancer targets.
Medarex expects to generate fully human monoclonal antibodies against these targets using its proprietary UltiMAb Human Antibody Development System®, and the two companies expect to jointly carry out initial validation studies.
The two companies plan to alternate the selection of antigen-antibody research programs to further develop and commercialize the antibodies independently.
The selecting party will have full development and commercialization rights to products arising from its selected research programs, and the other party will be entitled to receive milestone payments if milestones are achieved and royalties on commercial sales of any such products.
The selecting company may develop antibodies generated under this collaboration internally or through external partners.
"We are pleased with this new collaboration with Medarex as it combines the strength of our novel target discovery and validation with their expertise as a leader in developing human antibody therapeutics," said Kathy Ordonez, President of Celera.
"Our proteomics discovery platform continues to demonstrate value in identification of oncology targets for Celera and our partners, and this new relationship with Medarex allows us additional flexibility in advancing our broad pipeline of validated targets for additional future value."
"We are pleased with this opportunity to work with Celera and to pair targets discovered by their proprietary technology with our UltiMAb technology," said Donald L. Drakeman, President and CEO of Medarex.
"This collaboration provides us with an opportunity to further expand our base of potential new oncology therapeutics."
